Cover Image
市場調查報告書

亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場預測

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

出版商 GBI Research 商品編碼 358649
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場預測 Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
出版日期: 2016年05月01日 內容資訊: 英文 144 Pages
簡介

亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場,預計從2015年的27億美元,擴大到2022年的49億美元,預計2015年∼2022年以8.7%的年複合成長率成長。

本報告提供亞太地區的非小細胞肺癌 (NSCLC) 治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 上市產品

  • 概要
  • 化療
  • R. Tarceva (erlotinib) - Roche
  • Iressa (gefitinib) - AstraZeneca
  • Gilotrif (afatinib) - Boehringer Ingelheim
  • Xalkori (crizotinib) - Pfizer
  • Avastin (bevacizumab) - Roche
  • Opdivo (nivolumab) - Bristol-Myers Squibb
  • Alecensa (alectinib) - Roche
  • 結論
  • 上市產品的有效性和安全性比較

第4章 開發平台分析

  • 概要
  • 開發平台:各開發階段,分子類型,給藥途徑,計劃類型
  • 開發平台:各分子標的
  • 有前途的開發平台候補藥
  • 開發中產品的有效性和安全性比較
  • 產品競爭力架構

第5章 臨床實驗分析

  • 失敗率
  • 臨床實驗的規模
  • 臨床實驗的期間
  • 臨床實驗標準的摘要

第6章 複數方案的預測

  • 概要
  • 亞太地區市場
  • 印度
  • 中國
  • 澳洲
  • 韓國
  • 日本

第7章 市場動態 (推動因素與阻礙)

  • 推動因素
  • 障礙

第8章 交易與策略性整合

  • 共同開發交易
  • 許可證交易

第9章 附錄

圖表

目錄
Product Code: GBIHC408MR

Executive Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 - is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

Scope

The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%.

  • How will immunotherapies such as Keytruda contribute to the growth?
  • What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
  • What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
  • How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
  • How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict NSCLC market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Adenocarcinoma
    • 2.4.2. Squamous-Cell Carcinoma
    • 2.4.3. Large-Cell Carcinoma
    • 2.4.4. Immunotherapy
  • 2.5. Diagnosis
  • 2.6. Prognosis
  • 2.7. Treatment Guidelines and Options
    • 2.7.1. Treatment Algorithm
    • 2.7.2. First-Line Treatment
    • 2.7.3. Maintenance Therapy
    • 2.7.4. Second-Line Treatment
    • 2.7.5. Third-Line Therapy
    • 2.7.6. Adjuvant Therapy

3. Marketed Products

  • 3.1. Overview
  • 3.2. Chemotherapies
    • 3.2.1. Alimta (pemetrexed) - Eli Lilly
    • 3.2.2. Abraxane (paclitaxel) - Celgene
  • 3.3. Tarceva (erlotinib) - Roche
  • 3.4. Iressa (gefitinib) - AstraZeneca
  • 3.5. Gilotrif (afatinib) - Boehringer Ingelheim
  • 3.6. Xalkori (crizotinib) - Pfizer
  • 3.7. Avastin (bevacizumab) - Roche
  • 3.8. Opdivo (nivolumab) - Bristol-Myers Squibb
  • 3.9. Alecensa (alectinib) - Roche
  • 3.10. Conclusion
  • 3.11. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. Ipilimumab - Bristol-Myers Squibb
    • 4.4.2. Custirsen - OncoGenex
    • 4.4.3. Atezolizumab - Roche
    • 4.4.4. Necitumumab - Eli Lilly
    • 4.4.5. Rociletinib - Clovis
    • 4.4.6. Vaxira - Recombio
    • 4.4.7. Keytruda - Merck
    • 4.4.8. TG4010-Transgene
    • 4.4.9. Veliparib - AbbVie
    • 4.4.10. Abemaciclib - Eli Lilly
    • 4.4.11. Bavituximab - Peregrine Pharmaceuticals
    • 4.4.12. Cyramza (Ramucirumab) - Eli Lilly
    • 4.4.13. Zykadia (ceritinib/LDK378) - Novartis
    • 4.4.14. Tagrisso (osimertinib/AZD-9291) - AstraZeneca
    • 4.4.15. Dacomitinib - Pfizer
    • 4.4.16. Selumetinib - AstraZeneca
  • 4.5. Comparative Efficacy and Safety of Pipeline Products
  • 4.6. Product Competitiveness Framework

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Size
    • 5.2.1. Patient Enrollment per Product by Molecule Type and Stage of Development
    • 5.2.2. Patient Enrollment per Product by Molecular Target and Stage of Development
    • 5.2.3. Patient Enrollment per Trial by Molecule Type and Stage of Development
    • 5.2.4. Patient Enrollment per Trial by Molecular Target and Stage of Development
  • 5.3. Clinical Trial Duration
    • 5.3.1. Trial Duration by Molecule Type and Stage of Development
    • 5.3.2. Trial Duration by Molecular Target and Stage of Development
  • 5.4. Summary of Clinical Trial Metrics

6. Multi-scenario Forecast

  • 6.1. Overview
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. South Korea
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Japan
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size

7. Market Dynamics (Drivers and Barriers)

  • 7.1. Drivers
    • 7.1.1. Increasing pollution and passive smoking to drive the incidence
    • 7.1.2. Increasing Elderly Population and Incidence of NSCLC
    • 7.1.3. The Availability of Novel First- and Second-Line Therapy Options in Pipeline
    • 7.1.4. Increase in Mutation Testing to Drive Market Growth
    • 7.1.5. Diversified Healthcare Reform to Boost Market Growth
    • 7.1.6. Diversified Health Insurance System to Help Nurture Growth
  • 7.2. Barriers
    • 7.2.1. Patent Expiration of Branded Therapies to Affect NSCLC Market Growth
    • 7.2.2. High Prices of Therapeutics to Slow Down Market Growth
    • 7.2.3. Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India

8. Deals and Strategic Consolidations

  • 8.1. Co-development Deals
    • 8.1.1. Key Co-development Deals
  • 8.2. Licensing Deals
    • 8.2.1. Key Licensing Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Stage of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Investigational New Drug/ Clinical Trial Authorization-filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Summary of Multi-scenario Market Forecasts to 2022
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. References
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: NSCLC Therapeutics Market, Tumor Node Metastasis Classification
  • Table 2: NSCLC Therapeutics Market, Eastern Co-operative Oncology Group Criteria
  • Table 3: NSCLC Therapeutics Market, Treatment Options
  • Table 4: NSCLC Therapeutics Market, Global, All Pipeline Products, Discovery, 2015
  • Table 5: NSCLC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2015
  • Table 6: NSCLC Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2015
  • Table 7: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase I, 2015
  • Table 8: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase II, 2015
  • Table 9: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase III, 2015
  • Table 10: NSCLC Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2015
  • Table 11: NSCLC Therapeutics Market, APAC, Market Forecast, 2015-2022
  • Table 12: NSCLC Therapeutics Market, India, Market Forecast, 2015-2022
  • Table 13: NSCLC Therapeutics Market, China, Market Forecast, 2015-2022
  • Table 14: NSCLC Therapeutics Market, Australia, Market Forecast, 2015-2022
  • Table 15: NSCLC Therapeutics Market, South Korea, Market Forecast, 2015-2022
  • Table 16: NSCLC Therapeutics Market, Japan, Market Forecast, 2015-2022

List of Figures

  • Figure 1: NSCLC Therapeutics Market, Australia, Age-Specific Incidence Rate (100,000), 2000-2012
  • Figure 2: NSCLC Therapeutics Market, Global, Molecular Characteristic Frequency (%)
  • Figure 3: NSCLC Therapeutics Market, Market Heatmap, First-Line Products
  • Figure 4: NSCLC Therapeutics Market, Market Heatmap, Maintenance Products
  • Figure 5: NSCLC Therapeutics Market, Market Heatmap, Second-Line Products
  • Figure 6: NSCLC Therapeutics Market, Global, Pipeline, 2015
  • Figure 7: NSCLC Therapeutics Market, Global, Pipeline by Molecular Target, 2015
  • Figure 8: NSCLC Therapeutics Market, Pipeline by Molecular Target and Stage of Development
  • Figure 9: NSCLC Therapeutics Market, APAC, Ipilimumab Forecast ($m), 2017-2022
  • Figure 10: NSCLC Therapeutics Market, APAC, Custirsen Forecast ($m), 2019-2022
  • Figure 11: NSCLC Therapeutics Market, APAC, Atezolizumab Forecast ($m), 2017-2022
  • Figure 12: NSCLC Therapeutics Market, APAC, Necitumumab Forecast ($m), 2017-2022
  • Figure 13: NSCLC Therapeutics Market, APAC, Rociletinib Forecast ($m), 2018-2022
  • Figure 14: NSCLC Therapeutics Market, APAC, Vaxira Forecast ($m), 2019-2022
  • Figure 15: NSCLC Therapeutics Market, APAC, Keytruda Forecast ($m), 2017-2022
  • Figure 16: NSCLC Therapeutics Market, APAC, TG4010 Forecast ($m), 2021-2022
  • Figure 17: NSCLC Therapeutics Market, APAC, Veliparib Forecast ($m), 2019-2022
  • Figure 18: NSCLC Therapeutics Market, APAC, Abemaciclib Forecast ($m), 2019-2022
  • Figure 19: NSCLC Therapeutics Market, APAC, Bavituximab Forecast ($m), 2019-2022
  • Figure 20: NSCLC Therapeutics Market, APAC, Cyramza Forecast ($m), 2017-2022
  • Figure 21: NSCLC Therapeutics Market, APAC, Zykadia Forecast ($m), 2017-2022
  • Figure 22: NSCLC Therapeutics Market, APAC, Tagrisso Forecast ($m), 2016-2022
  • Figure 23: NSCLC Therapeutics Market, Pipeline Heatmap, First-Line Products
  • Figure 24: NSCLC Therapeutics Market, Pipeline Heatmap, Second-Line Products
  • Figure 25: NSCLC Therapeutics Market, Marketed and Pipeline Product Competitiveness Framework
  • Figure 26: NSCLC Therapeutics Market, Clinical Trial Attrition Rates (%)
  • Figure 27: NSCLC Therapeutics Market, Clinical Trial Attrition Rates by Molecule Type (%)
  • Figure 28: NSCLC Therapeutics Market, Clinical Trial Attrition Rates by Molecular Target (%)
  • Figure 29: NSCLC Therapeutics Market, Clinical Trial Size per Product by Molecule Type (participants)
  • Figure 30: NSCLC Therapeutics Market, Clinical Trial Size per Product Molecular Target (participants)
  • Figure 31: NSCLC Therapeutics Market, Clinical Trial Size per Individual Trial by Molecule Type (participants)
  • Figure 32: NSCLC Therapeutics Market, Clinical Trial Size per Individual Trial by Molecular Target (participants)
  • Figure 33: NSCLC Therapeutics Market, Clinical Trial Duration by Molecule Type (months)
  • Figure 34: NSCLC Therapeutics Market, Clinical Trial Duration by Molecular Target (months)
  • Figure 35: NSCLC Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 36: NSCLC Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 37: NSCLC Therapeutics Market, APAC, Treatment Patterns ('000), 2015-2022
  • Figure 38: NSCLC Therapeutics Market, APAC, Market Size ($bn), 2015-2022
  • Figure 39: NSCLC Therapeutics Market, India, Treatment Patterns ('000), 2015-2022
  • Figure 40: NSCLC Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
  • Figure 41: NSCLC Therapeutics Market, India, Market Size ($m), 2015-2022
  • Figure 42: NSCLC Therapeutics Market, China, Treatment Patterns ('000), 2015-2022
  • Figure 43: NSCLC Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
  • Figure 44: NSCLC Therapeutics Market, China, Market Size ($bn), 2015-2022
  • Figure 45: NSCLC Therapeutics Market, Australia, Treatment Patterns ('000), 2015-2022
  • Figure 46: NSCLC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
  • Figure 47: NSCLC Therapeutics Market, Australia, Market Size ($m), 2015-2022
  • Figure 48: NSCLC Therapeutics Market, South Korea, Treatment Patterns ('000), 2015-2022
  • Figure 49: NSCLC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
  • Figure 50: NSCLC Therapeutics Market, South Korea, Market Size ($m), 2015-2022
  • Figure 51: NSCLC Therapeutics Market, Japan, Treatment Patterns ('000), 2015-2022
  • Figure 52: NSCLC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
  • Figure 53: NSCLC Therapeutics Market, Japan, Market Size ($bn), 2015-2022
  • Figure 54: NSCLC Therapeutics Market, Co-development Deals by Territory, 2006-2015
  • Figure 55: NSCLC Therapeutics Market, Co-development Deals Overview, 2006-2015
  • Figure 56: NSCLC Therapeutics Market, Co-development by Molecule Type, 2006-2015
  • Figure 57: NSCLC Therapeutics Market, Co-development by Molecular Target, 2006-2015
  • Figure 58: NSCLC Therapeutics Market, Licensing Deals by Territory, 2006-2015
  • Figure 59: NSCLC Therapeutics Market, Licensing Deals Overview, 2006-2015
  • Figure 60: NSCLC Therapeutics Market, Licensing Deals by Molecule Type, 2006-2015
  • Figure 61: NSCLC Therapeutics Market, Licensing Deals by Molecular Target, 2006-2015
Back to Top